• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by GoodRx Holdings Inc.

    2/27/25 4:33:04 PM ET
    $GDRX
    EDP Services
    Technology
    Get the next $GDRX alert in real time by email
    S-8 1 gdrxforms-8fy24.htm S-8 GDRX Form S-8 FY24
    As filed with the Securities and Exchange Commission on February 27, 2025
    Registration No. 333-
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    FORM S-8
    REGISTRATION STATEMENT
    Under
    The Securities Act of 1933
    GoodRx Holdings, Inc.
    (Exact name of registrant as specified in its charter)
    Delaware
    47-5104396
    (State or other jurisdiction of
    incorporation or organization)
    (I.R.S. Employer
    Identification No.)
    2701 Olympic Boulevard
    Santa Monica, CA 90404
    (855) 268-2822
    (Address, including zip code and telephone number, including area code, of Registrant’s principal executive offices)
    GoodRx Holdings, Inc. 2020 Incentive Award Plan
    GoodRx Holdings, Inc. 2020 Employee Stock Purchase Plan
    (Full title of the plans)
    Christopher McGinnis
    Chief Financial Officer
    2701 Olympic Boulevard
    Santa Monica, CA 90404
    (855) 268-2822
    (Name, address, including zip code, and telephone number, including area code, of agent for service)
    Copies to:
    Marc D. Jaffe
    Benjamin J. Cohen
    Jenna Cooper
    Latham & Watkins LLP
    1271 Avenue of the Americas
    New York, NY 10020
    (212) 906-1200
    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller
    reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller
    reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
    Large accelerated filer
    ☐
    Accelerated filer
    ☒
    Non-accelerated filer
    ☐
    Smaller reporting company
    ☐
    Emerging growth company
    ☐
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
    complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.
    ☐
    EXPLANATORY NOTE
    This Registration Statement on Form S-8 is being filed with the Securities and Exchange Commission (the
    “Commission”) for the purpose of registering an additional 33,852,798 shares of Class A common stock, par value $0.0001 per
    share (the “Class A Common Stock”), of GoodRx Holdings, Inc. (the “Registrant”), issuable under the following employee
    benefit plans for which registration statements of the Registrant on Form S-8 (File No. 333-249069), Form S-8 (File No.
    333-254184), Form S-8 (File No. 333-263118), Form S-8 (File No. 333-270149) and Form S-8 (File No. 333-277511) are
    effective: (i) the GoodRx Holdings, Inc. 2020 Incentive Award Plan (the “2020 Plan”) and (ii) the GoodRx Holdings, Inc. 2020
    Employee Stock Purchase Plan (the “2020 ESPP”).
    Pursuant to General Instruction E of Form S-8, the contents of the above-referenced prior registration statements are
    incorporated into this Registration Statement by reference to the extent not modified or superseded hereby or by any subsequently
    filed document, which is incorporated by reference herein or therein.
    Item 8. EXHIBITS.
    Incorporated by Reference
    Exhibit
    Number
    Exhibit Description
    Form
    File
    Number
    Filing
    Date
    Exhibit
    Filed
    Herewith
    4.1
    Amended and Restated Certificate of
    Incorporation
    8-K
    001-39549
    9-28-2020
    3.1
    4.2
    Amended and Restated Bylaws
    8-K
    001-39549
    9-28-2020
    3.2
    4.3
    Form of Certificate of Class A Common
    Stock
    S-1/A
    333-248465
    8-28-2020
    4.1
    5.1
    Opinion of Latham & Watkins LLP
    X
    23.1
    Consent of PricewaterhouseCoopers LLP
    X
    23.2
    Consent of Latham & Watkins LLP
    (included in Exhibit 5.1)
    X
    24.1
    Power of Attorney
    X
    99.1
    GoodRx Holdings, Inc. 2020 Incentive
    Award Plan
    S-8
    333-249069
    9-25-2020
    99.2
    99.1.1
    Form of Option Agreement pursuant to
    2020 Incentive Award Plan
    S-1/A
    333-248465
    9-14-2020
    10.3.1
    99.1.2
    Form of Restricted Stock Unit Agreement
    pursuant to 2020 Incentive Award Plan
    S-1/A
    333-248465
    9-14-2020
    10.3.2
    99.1.5
    First Amendment to GoodRx Holdings, Inc.
    2020 Incentive Award Plan
    10-Q
    001-39549
    5-13-2021
    10.1
    99.1.6
    Form of Director Deferred Cash Fees RSU
    Agreement
    10-K
    001-39549
    2-29-2024
    10.18.1
    99.1.7
    Form of Director Deferred RSU Agreement
    10-K
    001-39549
    2-29-2024
    10.18.2
    99.2
    GoodRx Holdings, Inc. 2020 Employee
    Stock Purchase Plan
    S-1/A
    333-248465
    9-14-2020
    10.4
    107.1
    Filing Fee Table
    X
    SIGNATURES
    Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant certifies that it has reasonable grounds to
    believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on
    its behalf by the undersigned, thereunto duly authorized, in the City of Santa Monica, State of California, on this 27th day of
    February, 2025.
    GOODRX HOLDINGS, INC.
    By:
    /s/ Christopher McGinnis
    Christopher McGinnis
    Chief Financial Officer & Treasurer
    SIGNATURES AND POWER OF ATTORNEY
    We, the undersigned officers and directors of GoodRx Holdings, Inc., hereby severally constitute and appoint Wendy Barnes and
    Christopher McGinnis, and each of them singly (with full power to each of them to act alone), our true and lawful attorneys-in-
    fact and agents, with full power of substitution and resubstitution in each of them for him or her and in his or her name, place and
    stead, and in any and all capacities, to sign this registration statement and any and all amendments (including post-effective
    amendments) to this registration statement and all documents relating thereto, and to file the same, with all exhibits thereto, and
    other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and
    agents, and each of them, full power and authority to do and perform each and every act and thing requisite or necessary to be
    done in and about the premises, as full to all intents and purposes as he or she might or could do in person, hereby ratifying and
    confirming all that said attorneys-in-fact and agents or any of them, or their or his or her substitute or substitutes, may lawfully do
    or cause to be done by virtue hereof.
    Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the
    following persons in the capacities held on the dates indicated.
    Signature
    Title
    Date
    /s/ Wendy Barnes
    Chief Executive Officer, President & Director
    February 27, 2025
    Wendy Barnes
    (Principal Executive Officer)
    /s/ Christopher McGinnis
    Chief Financial Officer & Treasurer
    February 27, 2025
    Christopher McGinnis
    (Principal Financial Officer)
    /s/ Romin Nabiey
    Chief Accounting Officer
    February 27, 2025
    Romin Nabiey
    (Principal Accounting Officer)
    /s/ Trevor Bezdek
    Co-Chairman & Director
    February 27, 2025
    Trevor Bezdek
    /s/ Scott Wagner
    Co-Chairman & Director
    February 27, 2025
    Scott Wagner
    /s/ Christopher Adams
    Director
    February 27, 2025
    Christopher Adams
    /s/ Ronald E. Bruehlman
    Director
    February 27, 2025
    Ronald E. Bruehlman
    /s/ Ian T. Clark
    Director
    February 27, 2025
    Ian T. Clark
    /s/ Dipanjan Deb
    Director
    February 27, 2025
    Dipanjan Deb
    /s/ Douglas Hirsch
    Director
    February 27, 2025
    Douglas Hirsch
    /s/ Kelly J. Kennedy
    Director
    February 27, 2025
    Kelly J. Kennedy
    /s/ Gregory Mondre
    Director
    February 27, 2025
    Gregory Mondre
    /s/ Agnes Rey-Giraud
    Director
    February 27, 2025
    Agnes Rey-Giraud
    Get the next $GDRX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GDRX

    DatePrice TargetRatingAnalyst
    1/22/2026$2.75Buy → Hold
    Jefferies
    12/9/2025$3.00Underweight
    Barclays
    8/11/2025Strong Buy → Outperform
    Raymond James
    12/4/2024$5.00Neutral
    Mizuho
    8/9/2024$10.00Outperform → Strong Buy
    Raymond James
    5/23/2024$8.00 → $10.00Sector Perform → Outperform
    RBC Capital Mkts
    5/16/2024$10.00Mkt Perform → Outperform
    Raymond James
    4/10/2024$9.00Sector Weight → Overweight
    KeyBanc Capital Markets
    More analyst ratings

    $GDRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    GoodRx downgraded by Jefferies with a new price target

    Jefferies downgraded GoodRx from Buy to Hold and set a new price target of $2.75

    1/22/26 8:25:34 AM ET
    $GDRX
    EDP Services
    Technology

    Barclays initiated coverage on GoodRx with a new price target

    Barclays initiated coverage of GoodRx with a rating of Underweight and set a new price target of $3.00

    12/9/25 8:49:54 AM ET
    $GDRX
    EDP Services
    Technology

    GoodRx downgraded by Raymond James

    Raymond James downgraded GoodRx from Strong Buy to Outperform

    8/11/25 9:45:40 AM ET
    $GDRX
    EDP Services
    Technology

    $GDRX
    SEC Filings

    View All

    GoodRx Holdings Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - GoodRx Holdings, Inc. (0001809519) (Filer)

    12/12/25 4:26:49 PM ET
    $GDRX
    EDP Services
    Technology

    SEC Form 10-Q filed by GoodRx Holdings Inc.

    10-Q - GoodRx Holdings, Inc. (0001809519) (Filer)

    11/4/25 4:31:17 PM ET
    $GDRX
    EDP Services
    Technology

    GoodRx Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - GoodRx Holdings, Inc. (0001809519) (Filer)

    11/4/25 4:23:32 PM ET
    $GDRX
    EDP Services
    Technology

    $GDRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Wagner Scott bought $124,806 worth of shares (21,652 units at $5.76) (SEC Form 4)

    4 - GoodRx Holdings, Inc. (0001809519) (Issuer)

    12/4/23 4:35:10 PM ET
    $GDRX
    EDP Services
    Technology

    Wagner Scott bought $180,423 worth of shares (30,505 units at $5.91) (SEC Form 4)

    4 - GoodRx Holdings, Inc. (0001809519) (Issuer)

    11/30/23 4:41:35 PM ET
    $GDRX
    EDP Services
    Technology

    Wagner Scott bought $677,475 worth of shares (130,743 units at $5.18) (SEC Form 4)

    4 - GoodRx Holdings, Inc. (0001809519) (Issuer)

    11/17/23 7:08:30 PM ET
    $GDRX
    EDP Services
    Technology

    $GDRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Accounting Officer Nabiey Romin converted options into 12,663 shares and covered exercise/tax liability with 5,215 shares, increasing direct ownership by 5% to 172,923 units (SEC Form 4)

    4 - GoodRx Holdings, Inc. (0001809519) (Issuer)

    2/9/26 5:49:36 PM ET
    $GDRX
    EDP Services
    Technology

    Director Wagner Scott converted options into 31,394 shares, increasing direct ownership by 17% to 216,663 units (SEC Form 4)

    4 - GoodRx Holdings, Inc. (0001809519) (Issuer)

    1/21/26 5:20:35 PM ET
    $GDRX
    EDP Services
    Technology

    Officer Barnes Wendy Lynn converted options into 665,302 shares and covered exercise/tax liability with 237,309 shares (SEC Form 4)

    4 - GoodRx Holdings, Inc. (0001809519) (Issuer)

    1/15/26 5:19:15 PM ET
    $GDRX
    EDP Services
    Technology

    $GDRX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    GoodRx Powers Pricing for Leading Brand Medications on TrumpRx

    Brief Summary: GoodRx is a core integration partner for TrumpRx, powering the pricing for leading brand medications At launch, GoodRx is the integrated pricing source on TrumpRx for Pfizer, including over 30 of Pfizer's essential brand medications spanning women's health, arthritis, and more By unifying pricing, pharmacy enablement, and a trusted consumer experience, GoodRx enables pharma manufacturers to rapidly deploy and scale emerging pricing models with minimal operational lift GoodRx (NASDAQ:GDRX), the leading platform for prescription savings in the U.S., today announced that it is a key integration partner for pharmaceutical companies offering discounted cash prices on T

    2/5/26 7:44:00 PM ET
    $GDRX
    EDP Services
    Technology

    GoodRx Earns HITRUST i1 Certification for the Second Consecutive Year, Reinforcing Its Commitment to Protecting Healthcare Data at Scale

    Independent assessment validates GoodRx's continued leadership in cybersecurity and data protection GoodRx (NASDAQ:GDRX), the leading platform for prescription savings in the U.S., today announced it has earned its 2026 certification status for HITRUST i1 Certification for its prescription savings platform hosted on Amazon Web Services (AWS). This certification shows continuous dedication to GoodRx's prior HITRUST achievement and underscores the company's ongoing commitment to safeguarding sensitive healthcare information. The HITRUST i1 Certification demonstrates that GoodRx has met requirements defined by leading cybersecurity and regulatory frameworks, confirming that strong controls

    2/2/26 9:00:00 AM ET
    $GDRX
    EDP Services
    Technology

    60 Degrees Pharmaceuticals Expands Access to ARAKODA® with GoodRx Partnership

    GoodRx to offer prescription savings of up to 30% for ARAKODA® (tafenoquine)Collaboration designed to lower patient out-of-pocket costs and expand the reach of Company's marketing strategyPartnership will improve the affordability of ARAKODA at over 70,000 pharmacies nationwide for people planning travel to malaria-endemic regions WASHINGTON, Feb. 02, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP, SXTPW)) ("60 Degrees Pharma" or the "Company"), a pharmaceutical company focused on developing new medicines for vector-borne disease, today announced a partnership with GoodRx (NASDAQ:GDRX), the leading platform for prescription savings in the U.S., to offer eligible co

    2/2/26 8:01:00 AM ET
    $GDRX
    $SXTP
    EDP Services
    Technology
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GDRX
    Leadership Updates

    Live Leadership Updates

    View All

    GoodRx Appoints Amazon Pharmacy Veteran Laura Jensen as President of Pharma Solutions

    Seasoned industry leader tapped to help pharma reimagine their go-to-market strategies and direct-to-patient models GoodRx (NASDAQ:GDRX), the leading platform for medication savings in the U.S., today announced the appointment of Laura Jensen as Chief Commercial Officer and President of Pharma Solutions, effective July 28, 2025. In this role, Laura will lead the company's Pharma Manufacturer Solutions offering and oversee strategic initiatives aimed at growing and enhancing innovative partnerships across the pharmaceutical industry. Her deep cross-sector experience uniquely positions her to help revolutionize how patients access and afford their medications through the GoodRx platform. T

    7/28/25 9:00:00 AM ET
    $GDRX
    EDP Services
    Technology

    GoodRx Open Sources Lifecycle to Support Innovation in Software Development Velocity and Developer Productivity

    Public release of Lifecycle reflects company's commitment to transparency, innovation, and community collaboration GoodRx (NASDAQ:GDRX), the leading platform for medication savings in the U.S., today announced it is open-sourcing Lifecycle, a homegrown development tool designed to improve team velocity, streamline review workflows, and reduce infrastructure overhead. Lifecycle is now available to the public under the Apache 2.0 license, inviting developers and organizations to adopt, contribute to, and build upon the platform. The tool allows engineering, quality assurance, and platform teams to automatically spin up short-lived, isolated environments—known as ephemeral environments—for

    6/5/25 9:00:00 AM ET
    $GDRX
    EDP Services
    Technology

    GoodRx Appoints Aaron Crittenden as President of Rx Marketplace and Scott Pope, PharmD, as Chief Pharmacy Officer and Head of Clinical Engagement

    Accomplished healthcare executives will work to drive growth, strengthen industry partnerships, and enhance pharmacy innovation at GoodRx GoodRx (NASDAQ:GDRX), the leading platform for medication savings in the U.S., today announced the appointment of Aaron Crittenden as President of Rx Marketplace and Scott Pope, PharmD, as Chief Pharmacy Officer and Head of Clinical Engagement, effective immediately. Aaron will be responsible for the management and financial performance of GoodRx's Rx Marketplace offering, working with key retail pharmacy, pharmacy benefit manager (PBM), employer, and manufacturer partners. He will also play a critical role in shaping GoodRx's long-term growth strategy

    3/17/25 9:00:00 AM ET
    $GDRX
    EDP Services
    Technology

    $GDRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by GoodRx Holdings Inc.

    SC 13G/A - GoodRx Holdings, Inc. (0001809519) (Subject)

    11/14/24 12:29:56 PM ET
    $GDRX
    EDP Services
    Technology

    Amendment: SEC Form SC 13G/A filed by GoodRx Holdings Inc.

    SC 13G/A - GoodRx Holdings, Inc. (0001809519) (Subject)

    11/13/24 4:30:24 PM ET
    $GDRX
    EDP Services
    Technology

    Amendment: SEC Form SC 13G/A filed by GoodRx Holdings Inc.

    SC 13G/A - GoodRx Holdings, Inc. (0001809519) (Subject)

    11/12/24 4:02:41 PM ET
    $GDRX
    EDP Services
    Technology

    $GDRX
    Financials

    Live finance-specific insights

    View All

    GoodRx Announces Date for Fourth Quarter and Full Year 2025 Earnings Release and Conference Call

    GoodRx Holdings, Inc. (NASDAQ:GDRX) ("GoodRx" or the "Company"), the leading platform for prescription savings in the U.S., today announced it will release its fourth quarter and full year 2025 financial results after U.S. markets close on Wednesday, February 25, 2026. GoodRx management will also hold a conference call and webcast the following morning, Thursday, February 26, 2026 at 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time) to discuss the results and the Company's business outlook. To access the conference call, please pre-register using this link. Registrants will receive a confirmation with dial-in details and a unique passcode required to join. The call will also be webcast live

    1/28/26 4:05:00 PM ET
    $GDRX
    EDP Services
    Technology

    GoodRx Reports Third Quarter 2025 Results

    Company Maintains Full Year 2025 Revenue and Adjusted EBITDA Expectations; Raises Pharma Manufacturer Solutions Revenue Outlook to Approximately 35% Year-Over-Year Growth for 2025 GoodRx Holdings, Inc. (NASDAQ:GDRX) ("we," "us," "our," "GoodRx," or the "Company"), the leading platform for medication savings in the U.S., has released its financial results for the third quarter of 2025. Third Quarter 2025 Highlights Revenue of $196.0 million Net income of $1.1 million; Net income margin of 0.6% Adjusted Net Income1 of $28.8 million; Adjusted Net Income Margin1 of 14.7% Adjusted EBITDA1 of $66.3 million; Adjusted EBITDA Margin1 of 33.8% Net cash provided by operating activities of

    11/4/25 4:05:00 PM ET
    $GDRX
    EDP Services
    Technology

    GoodRx Announces Date for Third Quarter 2025 Earnings Release and Conference Call

    GoodRx Holdings, Inc. (NASDAQ:GDRX) ("GoodRx" or the "Company"), the leading platform for medication savings in the U.S., today announced it will release its third quarter 2025 financial results after U.S. markets close on Tuesday, November 4, 2025. GoodRx management will also hold a conference call and webcast the following morning, Wednesday, November 5, 2025 at 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time) to discuss the results and the Company's business outlook. To participate via telephone, please call (800) 715-9871 at least 10 minutes before the conference call is scheduled to begin. The conference ID is 9085550. The call will also be webcast live on the Company's investor relat

    10/8/25 4:05:00 PM ET
    $GDRX
    EDP Services
    Technology